Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas

Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, Inho Cha, Sung Won Cho, Jin Kim

Research output: Contribution to journalArticle

Abstract

Objectives: Ameloblastomas are the most common odontogenic epithelial tumors with high recurrence rate. The aim of this study was to identify apoptosis-related genes with recurrence of ameloblastomas and to evaluate its feasibility as a prognostic marker and as a target molecule preventing from recurrence. Materials and Methods: Public microarray data were analyzed. To evaluate their expression in ameloblastoma patients, immunohistochemical staining was performed in 89 human ameloblastoma tissues. Quantitative PCR was performed by use of ameloblastoma cell line (AM-1). Fluorescence activated cell sorting analysis and western blotting were conducted following transfection with siRNA. Further, AM-1 cells were implanted in the renal subcapsular layer of immunodeficient mice. Results: Microarray data analysis revealed that osteoprotegerin (OPG) and B-cell lymphoma 2 (Bcl-2) were the two most upregulated genes in ameloblastoma. Only Bcl-2 expression was significantly (p = 0.020) associated with recurrence in conservative treatment group (n = 17) among 89 patients. Silencing of Bcl-2 increased apoptosis in AM-1 cells in vitro and inhibited tumor nodule formation of AM-1 cells in vivo. Conclusion: These results suggest that Bcl-2 expression is a useful biomarker to predict recurrence of ameloblastomas, and as a therapeutic target molecule to prevent recurrence of ameloblastoma.

Original languageEnglish
Pages (from-to)1158-1168
Number of pages11
JournalOral Diseases
Volume25
Issue number4
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Ameloblastoma
B-Cell Lymphoma
Recurrence
Apoptosis
Odontogenic Tumors
Osteoprotegerin
Microarray Analysis
Small Interfering RNA
Genes
Transfection
Flow Cytometry
Biomarkers
Western Blotting
Staining and Labeling
Kidney
Cell Line
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Dentistry(all)

Cite this

Kim, Jue Young ; Kim, Jinsun ; Bazarsad, Shadavlonjid ; Cha, Inho ; Cho, Sung Won ; Kim, Jin. / Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas. In: Oral Diseases. 2019 ; Vol. 25, No. 4. pp. 1158-1168.
@article{77c5ad1e11a84df8ae3ffde067ba34ed,
title = "Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas",
abstract = "Objectives: Ameloblastomas are the most common odontogenic epithelial tumors with high recurrence rate. The aim of this study was to identify apoptosis-related genes with recurrence of ameloblastomas and to evaluate its feasibility as a prognostic marker and as a target molecule preventing from recurrence. Materials and Methods: Public microarray data were analyzed. To evaluate their expression in ameloblastoma patients, immunohistochemical staining was performed in 89 human ameloblastoma tissues. Quantitative PCR was performed by use of ameloblastoma cell line (AM-1). Fluorescence activated cell sorting analysis and western blotting were conducted following transfection with siRNA. Further, AM-1 cells were implanted in the renal subcapsular layer of immunodeficient mice. Results: Microarray data analysis revealed that osteoprotegerin (OPG) and B-cell lymphoma 2 (Bcl-2) were the two most upregulated genes in ameloblastoma. Only Bcl-2 expression was significantly (p = 0.020) associated with recurrence in conservative treatment group (n = 17) among 89 patients. Silencing of Bcl-2 increased apoptosis in AM-1 cells in vitro and inhibited tumor nodule formation of AM-1 cells in vivo. Conclusion: These results suggest that Bcl-2 expression is a useful biomarker to predict recurrence of ameloblastomas, and as a therapeutic target molecule to prevent recurrence of ameloblastoma.",
author = "Kim, {Jue Young} and Jinsun Kim and Shadavlonjid Bazarsad and Inho Cha and Cho, {Sung Won} and Jin Kim",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/odi.13070",
language = "English",
volume = "25",
pages = "1158--1168",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "4",

}

Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas. / Kim, Jue Young; Kim, Jinsun; Bazarsad, Shadavlonjid; Cha, Inho; Cho, Sung Won; Kim, Jin.

In: Oral Diseases, Vol. 25, No. 4, 01.05.2019, p. 1158-1168.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas

AU - Kim, Jue Young

AU - Kim, Jinsun

AU - Bazarsad, Shadavlonjid

AU - Cha, Inho

AU - Cho, Sung Won

AU - Kim, Jin

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Objectives: Ameloblastomas are the most common odontogenic epithelial tumors with high recurrence rate. The aim of this study was to identify apoptosis-related genes with recurrence of ameloblastomas and to evaluate its feasibility as a prognostic marker and as a target molecule preventing from recurrence. Materials and Methods: Public microarray data were analyzed. To evaluate their expression in ameloblastoma patients, immunohistochemical staining was performed in 89 human ameloblastoma tissues. Quantitative PCR was performed by use of ameloblastoma cell line (AM-1). Fluorescence activated cell sorting analysis and western blotting were conducted following transfection with siRNA. Further, AM-1 cells were implanted in the renal subcapsular layer of immunodeficient mice. Results: Microarray data analysis revealed that osteoprotegerin (OPG) and B-cell lymphoma 2 (Bcl-2) were the two most upregulated genes in ameloblastoma. Only Bcl-2 expression was significantly (p = 0.020) associated with recurrence in conservative treatment group (n = 17) among 89 patients. Silencing of Bcl-2 increased apoptosis in AM-1 cells in vitro and inhibited tumor nodule formation of AM-1 cells in vivo. Conclusion: These results suggest that Bcl-2 expression is a useful biomarker to predict recurrence of ameloblastomas, and as a therapeutic target molecule to prevent recurrence of ameloblastoma.

AB - Objectives: Ameloblastomas are the most common odontogenic epithelial tumors with high recurrence rate. The aim of this study was to identify apoptosis-related genes with recurrence of ameloblastomas and to evaluate its feasibility as a prognostic marker and as a target molecule preventing from recurrence. Materials and Methods: Public microarray data were analyzed. To evaluate their expression in ameloblastoma patients, immunohistochemical staining was performed in 89 human ameloblastoma tissues. Quantitative PCR was performed by use of ameloblastoma cell line (AM-1). Fluorescence activated cell sorting analysis and western blotting were conducted following transfection with siRNA. Further, AM-1 cells were implanted in the renal subcapsular layer of immunodeficient mice. Results: Microarray data analysis revealed that osteoprotegerin (OPG) and B-cell lymphoma 2 (Bcl-2) were the two most upregulated genes in ameloblastoma. Only Bcl-2 expression was significantly (p = 0.020) associated with recurrence in conservative treatment group (n = 17) among 89 patients. Silencing of Bcl-2 increased apoptosis in AM-1 cells in vitro and inhibited tumor nodule formation of AM-1 cells in vivo. Conclusion: These results suggest that Bcl-2 expression is a useful biomarker to predict recurrence of ameloblastomas, and as a therapeutic target molecule to prevent recurrence of ameloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=85063010633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063010633&partnerID=8YFLogxK

U2 - 10.1111/odi.13070

DO - 10.1111/odi.13070

M3 - Article

VL - 25

SP - 1158

EP - 1168

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 4

ER -